Sintilimab plus Chemotherapy

Phase 3Small molecule

Sintilimab plus Chemotherapy is one of 69 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

SintilimabRecruiting

Adjuvant TreatmentRecruiting

TransplantationEnrolling by invitation

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

SintilimabPhase 2

Recruiting

Adjuvant TreatmentPhase 2

Recruiting

TransplantationPhase 3

Enrolling by invitation

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

19 2

Navelbine

PPierre Fabre Medicament

Phase 3

24 3

Pyrotinib

HHengrui Therapeutics, Inc.

Phase 3

3 4

Sintilimab plus Chemotherapy

FFudan University

Phase 3

1 5

WX-0593

Qilu Pharmaceutical Co., Ltd.

Phase 3

4 6

Remeron

OOrganon and Co

Preclinical

1 7

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—9

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—10

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Adjuvant Treatment

NCT06761846

Clinical

Trials by Indication[1]

Transplantation1 trial

Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer

Enrolling by invitation·FFirst Affiliated Hospital of Ningbo University·Phase 4·NCT06931808·20 enrolled

Non-Small Cell Lung Cancer1 trial

Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer

Unknown status·TThe First Hospital of Jilin University··NCT06267144·20 enrolled

Adjuvant Treatment1 trial

Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ

Recruiting·—·Phase 2·NCT06761846·70 enrolled

Sintilimab1 trial

Adriamycin and Ifosfamide Combined With Sintilimab

Recruiting·SSun Yat-sen University·Phase 2·NCT04589754·176 enrolled

Locally Advanced1 trial

Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC

Completed·FFudan University·Phase 2·NCT03985046·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Sintilimab plus Chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sintilimab plus Chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sintilimab plus Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFudan University

Sintilimab plus Chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Transplantation1 trial

Non-Small Cell Lung Cancer1 trial

Adjuvant Treatment1 trial

Sintilimab1 trial

Locally Advanced1 trial

References

Drug Info

Quick Facts

Related News